×
0 0 0.00823045267489713 0.00823045267489713 0.0288065843621398 0.0493827160493828 0.0493827160493828 0.0596707818930041
Stock impact report

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

Zynerba Pharmaceuticals (ZYNE)  More Company Research Source: GlobeNewswire
Last zynerba pharmaceuticals earnings: 8/6 06:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.zynerba.com
PDF - Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 - Presentation Today at the 57th Annual Meeting of the American College of Neuropsychopharmacology - DEVON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, [Read more]
Impact snapshot Event time: ZYNE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ZYNE alerts
from News Quantified
Opt-in for
ZYNE alerts

from News Quantified
Opt-in for
ZYNE alerts

from News Quantified